Skip to main content

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

By: Newsfile

Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies.

Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics. The report, The RNA Revolution: Unleashing the Therapeutic Potential of RNAi, highlights the potential of RNA therapeutics and companies leveraging RNAi technologies are in particular focus as we believe this will be a meaningful area of development.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways

  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.

  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.

Cannot view this image? Visit:

Click image above to view full announcement.

About Stonegate Healthcare

The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.

Shiv Kapoor

Stonegate Healthcare Partners
(214) 987-4121

Source: Stonegate Healthcare Partners (SHP)

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.